IGI Logo

Venus Remedies is currently trading at Rs. 311.50, up by 0.75 points or 0.24% from its previous closing of Rs. 310.75 on the BSE.

The scrip opened at Rs. 311.55 and has touched a high and low of Rs. 315.20 and Rs. 309.05 respectively. So far 4581 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 429.60 on 05-Jan-2024 and a 52 week low of Rs. 260.00 on 06-Nov-2023.

Last one week high and low of the scrip stood at Rs. 331.00 and Rs. 303.50 respectively. The current market cap of the company is Rs. 414.51 crore.

The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.18% and 57.06% respectively.

Venus Remedies has received Good Manufacturing Practices (GMP) approval with Pharmaceutical Inspection Co-operation Scheme (PIC/S) accreditation from the National Pharmaceutical Regulatory Ageney (NPRA) of Malaysia for its state-of-the-art robotic pre-filled syringe (PFS) facility at its Baddi unit.

This marks the first PIC/S GMP accreditation for Venus Remedies' PFS facility, adding to the GMPs already secured by the company from more than 25 regulatory authorities, including the WHO, European Union and Saudi Arabia. The company has more than 35 marketing authorizations for its flagship PFS drug, enoxaparin, from various important markets like Saudi Arabia, Azerbaijan, Philippines, Myanmar, Kenya, Moldova, and Nepal.

The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities as it will enable Venus Remedies to seek quicker approvals from other PIC/S member countries owing to mutual recognition of this coveted certification among member states. This achievement will not only pave the way for the company's rapid expansion in new markets, but also enhance its ability to cater to the growing global demand for enoxaparin.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.